NCT00099619 - Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy | Biotech Hunter

Enrollment

138

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide/insulin glargine

Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels

DRUG

insulin glargine/exenatide

Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks

Trial Locations (26)

Unknown

Research Site, Westmead

Research Site, Daw Park

Research Site, Fullarton

Research Site, Box Hill

Research Site, East Ringwood

Research Site, Athens

Research Site, Piraeus

Research Site, Thessaloniki

Research Site, Budapest

Research Site, Gyula

Research Site, Pécs

Research Site, Veszprém

Research Site, Zalaegerszeg

Research Site, Bari

Research Site, Bergamo

Research Site, Catania

Research Site, Milan

Research Site, Perugia

Research Site, Rome

Research Site, Guadalajara

Research Site, Zapopan

Research Site, Monterrey

Research Site, Mexico City

Research Site, Bydgoszcz

Research Site, Gdansk

Research Site, Lublin